Related Experiment Video
Updated: May 27, 2026
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia
Maxime Berthelot-Richer1, Brigitte Boilard, Annie Morin
1Division of Hematology and Clinical Pharmacy, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada.
Background:
Refractoriness to platelet (PLT) transfusion is a feared, life-threatening complication in hematology-oncology patients. Despite increased PLT requirement and treatment costs, the clinical management is difficult and these patients had less favorable outcomes.
Case Report:
We report on the efficacy of the thrombopoietic agent romiplostim in a patient with acute myeloid leukemia with chemotherapy-induced transfusion-refractory thrombocytopenia.
Conclusion:
Romiplostim could be very helpfull in the management of AML patients with transfusion refractory thrombocytopenia.
